← Human Trials & Peer-Reviewed Studies
Efficacy and safety of [amount hidden] desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program
Plain-language guide to PMID 31397969 (2020): double-blind randomized controlled trial study of Vasopressin and Desmopressin.
Key Facts
- PMID
- 31397969
- Journal
- Lower urinary tract symptoms
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Yamaguchi O et al. (6 authors)
- DOI
- 10.1111/luts.12276
- Registered trial
- NCT02904759, NCT02905682
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.
Two Phase 3 randomized double-blind placebo-controlled studies of 342 males and 190 females with nocturia due to NP were conducted.
The primary endpoint was change from baseline in mean number of nocturnal voids.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
In addition, time to first awakening to void, nocturnal urine volume, NP index (NPI), and quality of life were assessed during a 12-week treatment period.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.
The timeline in the abstract includes 12 weeks.
What Was Measured
The primary endpoint was change from baseline in mean number of nocturnal voids.
PubMed files the paper under topics including Antidiuretic Agents, Deamino Arginine Vasopressin, Japan, Nocturia, Polyuria and Tablets.
The authors tagged it with the keywords desmopressin and nocturnal polyuria.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin over 12 weeks.
The publication is from 2020 (Lower urinary tract symptoms), a journal based in Australia.
More context: the Vasopressin compound page and the Desmopressin compound page.
Our Notes on the Compounds
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.